TENX (Tenax Therapeutics Inc) רווח למניה ב-12 החודשים האחרונים

Tenax Therapeutics (TENX) is actively expanding its line of pulmonary hypertension treatments, addressing critical gaps in cardiology. The current EPS YoY TTM growth rate reflects the dynamics of this process, with the current mark standing at -23.00. Success is based on partnerships with scientific centers and the creation of a comprehensive treatment environment that improves patient survival rates through the implementation of innovative therapeutic solutions.
Tenax Therapeutics Inc. - פילוחים אנליטיים ומדדי מפתח (TENX)

Tenax Therapeutics (TENX) investments in energy-efficient logistics and chemical waste disposal directly impact net income, which is reflected in the earnings per share trend. By analyzing the annual change in EPS (TTM), an investor assesses the growth rate of trailing profits relative to the previous year, where peak values often signal the exhaustion of growth drivers and an impending correction in the cost of capital.